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Abstract	  
	  
The	  main	  focus	  of	  this	  paper	  was	  to	  evaluate	  possible	  demographic	  and	  clinical	  characteristics	  
associated	  with	  a	  woman’s	  choice	  of	  breast	  conserving	  surgery	  (BCS),	  unilateral	  mastectomy	  (ULM),	  or	  
bilateral	  risk	  reduction	  mastectomy	  (BRRM).	  The	  cohort	  consisted	  of	  patients	  presenting	  to	  the	  City	  of	  
Hope	  National	  Medical	  Center	  with	  ductal	  carcinoma	  in	  situ	  breast	  cancer	  who	  elected	  to	  have	  cancer	  
directed	  surgery	  	  (N=305).	  	  Analyses	  to	  examine	  associations	  of	  patient	  characteristics	  with	  type	  of	  
surgery	  were	  conducted	  using	  a	  multinomial	  logistic	  regression.	  	  Results	  showed	  that	  older	  women	  were	  
more	  likely	  to	  choose	  breast	  conserving	  surgery	  over	  bilateral	  risk	  reduction	  mastectomy	  than	  younger	  
women	  (OR=6.64,	  95%	  CI=2.02-­‐21.84).	  	  Women	  diagnosed	  between	  1997	  and	  2004	  were	  more	  likely	  to	  
choose	  BCS	  over	  BRRM	  than	  patients	  more	  recently	  (2005-­‐2012),	  (OR=3.91,	  95%	  CI=1.48-­‐10.33).	  Women	  
with	  small	  tumors	  (<2cm)	  and	  multicentric	  disease,	  were	  also	  more	  likely	  to	  choose	  BCS	  over	  BRRM	  than	  
women	  with	  large	  tumors	  2cm	  or	  more	  (OR=3.35,	  95%	  CI=1.24-­‐9.05)	  and	  those	  without	  multicentric	  
disease	  (OR=6.69,	  95%	  CI=2.44,	  18.32).	  Those	  with	  a	  positive	  hormone	  receptor	  status	  were	  more	  likely	  
to	  choose	  BCS	  over	  BRRM	  than	  those	  with	  an	  unknown	  hormone	  receptor	  status	  (OR=5.28,	  95%	  
CI=1.99-­‐13.96),	  while	  there	  was	  no	  association	  found	  between	  negative	  and	  positive	  hormone	  receptor	  
status	  and	  surgical	  choice.	  	  Comparisons	  were	  not	  significant	  when	  examining	  likeliness	  of	  choosing	  
unilateral	  mastectomy	  over	  BRRM.	  Binomial	  logistic	  regression	  was	  conducted	  to	  investigate	  likeliness	  of	  
undergoing	  hormone	  therapy	  for	  those	  patients	  who	  chose	  not	  to	  get	  BRRM,	  and	  the	  cohort	  was	  
reduced	  to	  patients	  with	  at	  least	  270	  days	  follow-­‐up	  (N=243).	  Results	  found	  women	  with	  positive	  or	  
unknown	  hormone	  receptor	  status	  were	  substantially	  more	  likely	  to	  undergo	  hormone	  therapy	  than	  
women	  with	  a	  negative	  hormone	  receptor	  status	  (OR=15.22,	  95%	  CI=3.25-­‐71.24,	  and	  OR=12.07,	  95%	  
CI=2.60-­‐56.05	  respectively).	  The	  interaction	  between	  age	  at	  diagnosis	  and	  radiation	  therapy	  use	  also	  
showed	  that	  for	  a	  woman	  who	  has	  not	  received	  radiation	  therapy,	  the	  estimated	  odds	  of	  undergoing	  
hormone	  therapy	  were	  3.35	  times	  higher	  for	  those	  between	  50	  and	  64	  years	  of	  age	  compared	  to	  those	  
younger	  than	  50	  years	  (95%	  CI=1.25-­‐8.99).	  	  Finally	  survival	  analysis	  was	  conducted	  to	  examine	  if	  BRRM	  
impacts	  the	  chances	  of	  survival	  in	  women	  with	  DCIS	  breast	  cancer.	  The	  proportion	  of	  deaths	  in	  this	  
disease	  subset	  is	  small	  (2.3%),	  and	  there	  wasn’t	  enough	  evidence	  to	  conclude	  a	  significant	  difference	  in	  
survival	  based	  on	  surgery	  type.	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Introduction	  
	  
Ductal	  Carcinoma	  In	  Situ	  (DCIS)	  is	  a	  form	  of	  breast	  cancer	  associated	  with	  a	  higher	  risk	  for	  
subsequent	  contralateral	  breast	  cancer.	  The	  main	  choice	  of	  treatment	  is	  surgery	  with	  or	  without	  
adjuvant	  radiation	  therapy	  and/or	  hormone	  therapy.	  One	  of	  the	  more	  aggressive	  measures	  for	  
preventing	  contralateral	  breast	  cancer	  is	  for	  a	  woman	  to	  get	  bilateral	  risk	  reduction	  mastectomy,	  which	  
consists	  of	  removing	  the	  breast	  with	  the	  tumor	  as	  well	  as	  the	  unaffected	  breast.	  When	  a	  woman	  has	  
both	  breasts	  removed	  she	  doesn’t	  need	  to	  go	  on	  to	  get	  further	  treatment.	  More	  and	  more	  patients	  
seem	  to	  be	  choosing	  this	  procedure	  and	  doctors	  would	  like	  to	  investigate	  what	  characteristics	  of	  a	  
patient	  lead	  to	  this	  choice.	  This	  project	  examined	  certain	  demographic	  and	  clinical	  characteristics	  of	  City	  
of	  Hope	  breast	  cancer	  patients	  to	  see	  if	  the	  likeliness	  of	  a	  patient	  choosing	  a	  bilateral	  mastectomy	  can	  
be	  predicted.	  There	  were	  three	  main	  research	  questions	  addressed	  in	  this	  project.	  The	  first	  is	  what	  
factors	  influenced	  the	  risk	  reduction	  choice	  a	  patient	  made,	  between	  breast	  conserving	  surgery	  
(lumpectomy),	  unilateral	  mastectomy,	  or	  bilateral	  risk	  reduction	  mastectomy.	  The	  second	  research	  
question	  is	  of	  those	  women	  who	  choose	  not	  to	  get	  a	  bilateral	  risk	  reduction	  mastectomy,	  what	  factors	  
predict	  their	  choice	  of	  whether	  or	  not	  they	  had	  hormone	  therapy.	  The	  final	  question	  of	  interest	  is	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Methods	  
Data	  
The	  data	  used	  for	  this	  analysis	  comes	  from	  breast	  cancer	  patients	  presenting	  to	  the	  City	  of	  Hope	  
National	  Medical	  Center	  between	  July	  1997	  and	  February	  2012.	  Only	  patients	  with	  a	  breast	  cancer	  
histology	  of	  DCIS	  for	  the	  episode	  of	  interest,	  at	  least	  90	  days	  of	  good	  quality	  follow-­‐up	  data	  post	  
presentation,	  an	  overall	  programmed	  stage	  0	  at	  diagnosis,	  and	  who	  had	  a	  definitive	  surgery	  were	  
included	  (N=305).	  	  The	  timing	  rule	  of	  90	  days	  post	  diagnosis	  was	  chosen	  to	  ensure	  adequate	  time	  to	  
allow	  for	  definitive	  surgery.	  Additionally	  for	  the	  hormone	  therapy	  analysis,	  this	  cohort	  was	  further	  
reduced	  to	  only	  patients	  with	  at	  least	  270	  days	  of	  good	  quality	  follow-­‐up	  data	  post	  presentation	  and	  
excluded	  patients	  with	  bilateral	  risk	  reduction	  mastectomy	  (N=243).	  More	  time	  was	  allowed	  for	  the	  
hormone	  therapy	  analysis	  to	  allow	  for	  time	  to	  initiate	  adjuvant	  hormone	  therapy	  post-­‐surgery.	  	  
The	  data	  tables	  came	  from	  a	  relational	  database	  model	  and	  were	  accessed	  using	  SAS.	  	  There	  
were	  raw	  data	  sets	  that	  contained	  the	  data	  entered	  directly	  into	  the	  database,	  as	  well	  as	  derived	  data	  
sets	  that	  were	  manipulations	  of	  the	  raw	  data	  using	  predefined	  algorithms.	  Each	  data	  table	  had	  a	  data	  
dictionary	  used	  to	  explain	  variable	  meanings	  and	  coding,	  as	  well	  as	  pre-­‐defined	  SAS	  formats.	  	  Additional	  
formats	  were	  created	  for	  use	  in	  the	  analysis	  to	  collapse	  and	  categorize	  the	  variables	  of	  interest.	  	  	  
A	  large	  part	  of	  this	  project	  was	  preparing	  the	  data	  sets	  for	  final	  analysis.	  The	  data	  needed	  to	  be	  
narrowed	  down	  to	  include	  only	  a	  subset	  of	  patients	  and	  only	  certain	  variables	  of	  interest	  from	  the	  
various	  data	  sets.	  Some	  aspects	  of	  data	  preparation	  involved	  detailed	  programming	  and	  data	  
manipulation.	  For	  example	  women	  who	  had	  bilateral	  risk	  reduction	  mastectomies	  have	  two	  mastectomy	  
records	  stored	  as	  different	  rows	  in	  the	  data	  table.	  This	  information	  was	  then	  combined	  with	  the	  
laterality	  of	  the	  cancer	  to	  compare	  the	  side	  of	  the	  surgery	  in	  order	  to	  create	  the	  surgical	  choice	  variable.	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Variables	  of	  Interest	  
Initially	  ten	  predictors	  of	  interest	  that	  relate	  to	  treatment	  choice	  were	  defined.	  	  Age	  was	  defined	  
as	  the	  woman’s	  age	  at	  diagnosis	  with	  breast	  cancer,	  and	  was	  categorized	  based	  on	  meaningful	  clinical	  
specifications.	  	  	  Race	  was	  derived	  from	  the	  woman’s	  racial	  background	  and	  Spanish/Hispanic	  ethnicity.	  
Education	  referred	  to	  the	  highest	  level	  of	  education	  completed	  at	  time	  of	  diagnosis.	  Year	  of	  diagnosis	  
was	  categorized	  as	  1997-­‐2004,	  or	  2005-­‐2012	  and	  included	  as	  a	  predictor	  to	  see	  if	  the	  trend	  of	  bilateral	  
risk	  reduction	  mastectomies	  was	  a	  more	  recent	  occurrence.	  	  Histological	  grade	  referred	  to	  a	  system	  that	  
is	  used	  to	  classify	  cancer	  cells	  in	  terms	  of	  how	  abnormal	  they	  look	  under	  a	  microscope	  and	  how	  quickly	  
the	  tumor	  is	  likely	  to	  grow	  and	  spread.	  This	  can	  be	  an	  important	  factor	  when	  developing	  a	  treatment	  
plan	  and	  was	  therefore	  a	  variable	  of	  consideration	  in	  predicting	  surgical	  choice.	  A	  woman’s	  type	  of	  
health	  insurance	  was	  also	  suspected	  to	  impact	  treatment	  decisions.	  Tumor	  size	  was	  measured	  as	  the	  
size	  of	  mass	  in	  centimeters	  as	  established	  by	  surgery,	  which	  was	  under	  consideration	  to	  investigate	  if	  
larger	  tumors	  impacted	  treatment	  decisions.	  This	  variable	  is	  categorized	  as	  either	  less	  than	  2cm,	  2cm	  or	  
more,	  or	  unknown,	  as	  doctors	  consider	  2cm	  to	  be	  the	  cutoff	  between	  small	  and	  large	  tumors.	  
Multicentric	  disease	  involves	  two	  or	  more	  distinct	  primary	  tumors,	  usually	  in	  different	  quadrants	  of	  the	  
breast.	  Menopausal	  status	  was	  of	  interest	  in	  regards	  to	  whether	  a	  woman	  is	  pre	  or	  post	  menopause.	  
Hormone	  receptor	  status	  was	  included	  as	  a	  combination	  of	  the	  patient’s	  estrogen	  and	  progesterone	  
receptor	  status	  at	  diagnosis.	  About	  75%	  of	  women	  with	  breast	  cancer	  have	  tumors	  that	  contain	  
estrogen	  receptors	  (called	  ER-­‐positive).	  About	  65%	  of	  these	  are	  also	  PR-­‐positive,	  meaning	  they	  grow	  in	  
response	  to	  the	  hormone	  progesterone.	  Women	  who	  are	  ER/PR	  positive	  are	  more	  likely	  to	  respond	  to	  
hormone	  treatment	  than	  women	  who	  are	  ER/PR	  negative	  and	  therefore	  may	  not	  need	  to	  consider	  
aggressive	  surgery	  as	  an	  option.	  
For	  the	  hormone	  therapy	  analysis,	  all	  of	  the	  previously	  described	  variables	  were	  also	  of	  interest.	  
In	  addition,	  the	  surgical	  choice,	  BCS	  or	  unilateral	  mastectomy,	  was	  also	  of	  interest.	  Surgical	  margins	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were	  determined	  during	  or	  after	  surgery	  when	  a	  pathologist	  examines	  the	  rim	  of	  tissue	  to	  be	  sure	  it’s	  
clear	  of	  any	  cancer	  cells.	  If	  the	  surgical	  margins	  are	  negative,	  then	  no	  cancer	  cells	  were	  seen	  at	  the	  outer	  
edge	  of	  the	  tissue	  that	  was	  removed.	  However	  if	  the	  margins	  are	  positive,	  cancer	  cells	  came	  right	  out	  to	  
the	  edge	  of	  the	  removed	  tissue	  and	  this	  might	  have	  been	  a	  factor	  in	  predicting	  a	  woman’s	  likeliness	  to	  
undergo	  hormone	  therapy.	  The	  radiation	  therapy	  variable	  took	  into	  consideration	  whether	  or	  not	  a	  
patient	  has	  received	  radiation	  therapy	  which	  uses	  high-­‐energy	  radiation	  to	  kill	  cancer	  cells	  by	  damaging	  
their	  DNA.	  	  
All	  of	  the	  variables	  under	  consideration	  for	  analysis	  of	  surgical	  choice	  were	  also	  considered	  
potential	  adjustment	  variables	  for	  survival	  analysis	  (age,	  race,	  education,	  year,	  grade,	  insurance,	  tumor	  
size,	  multicentric	  disease,	  menopausal	  status,	  and	  hormone	  receptor	  status).	  	  	  
Statistical	  Analysis	  
Descriptive	  statistics	  were	  obtained	  in	  SAS	  to	  gain	  a	  better	  understanding	  of	  patterns	  in	  the	  data	  
based	  on	  surgical	  choice.	  For	  hormone	  therapy	  the	  frequencies	  and	  percentages	  of	  each	  variable	  
categorized	  by	  whether	  or	  not	  the	  patient	  received	  hormone	  therapy	  were	  also	  reviewed.	  These	  
descriptives	  also	  contained	  the	  univariate	  p-­‐values	  for	  each	  variable	  obtained	  using	  logistic	  regression,	  
based	  on	  the	  relevant	  outcome.	  	  
Multinomial	  logistic	  regression	  was	  used	  to	  predict	  the	  likeliness	  of	  a	  patient	  choosing	  breast	  
conserving	  surgery,	  unilateral	  mastectomy,	  or	  bilateral	  risk	  reduction	  mastectomy.	  Multinomial	  logistic	  
regression	  was	  run	  using	  PROC	  LOGISTIC	  in	  SAS	  and	  the	  link=glogit	  option.	  This	  option	  fit	  the	  generalized	  
logit	  function	  where	  each	  nonreference	  response	  category	  was	  contrasted	  with	  the	  reference	  category.	  
Bilateral	  Risk	  Reduction	  Mastectomy	  (BRRM)	  was	  used	  as	  the	  reference	  response	  category	  as	  it	  is	  the	  
surgical	  choice	  of	  interest	  for	  comparison.	  The	  saturated	  model	  included	  potential	  predictions	  with	  
univariate	  p-­‐values	  less	  than	  0.2:	  age,	  education,	  year,	  insurance,	  tumor	  size,	  multicentric	  disease,	  
menopausal	  status,	  and	  hormone	  receptor	  status.	  From	  this	  a	  predictor	  with	  the	  largest	  p-­‐value	  was	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eliminated	  from	  the	  model	  until	  all	  remaining	  predictors	  were	  significant	  at	  the	  0.05	  level.	  A	  priori	  
interactions	  with	  age	  were	  also	  tested	  and	  only	  included	  if	  they	  were	  found	  be	  useful	  contributors	  to	  the	  
model.	  Multinomial	  logistic	  regression	  produced	  two	  different	  regression	  equations.	  The	  first	  referred	  to	  
the	  likeliness	  of	  a	  woman	  choosing	  breast	  conserving	  surgery	  over	  a	  bilateral	  risk	  reduction	  mastectomy.	  
The	  second	  referred	  to	  the	  likeliness	  of	  a	  woman	  choosing	  a	  unilateral	  mastectomy	  over	  a	  bilateral	  risk	  
reduction	  mastectomy.	  Results	  included	  the	  type	  3	  analysis	  of	  effects	  p-­‐values,	  odds	  ratio	  estimates	  and	  
95%	  confidence	  intervals	  for	  the	  odds	  ratios	  for	  each	  of	  the	  comparisons	  to	  BRRM.	  
Logistic	  regression	  assumptions	  were	  checked	  for	  the	  final	  model.	  The	  first	  assumption	  was	  that	  
there	  is	  linearity	  between	  the	  logits	  and	  explanatory	  variables.	  This	  assumption	  does	  not	  apply	  for	  this	  
analysis	  however	  because	  the	  explanatory	  variables	  were	  categorical.	  The	  independent	  observations	  
assumption	  was	  also	  satisfied	  because	  we	  can	  assume	  one	  patient’s	  experience	  with	  breast	  cancer	  has	  
nothing	  to	  do	  with	  another	  patient’s	  experience.	  There	  were	  305	  patients	  in	  the	  final	  analysis	  data	  set	  so	  
the	  decent	  sample	  size	  assumption	  was	  met.	  Explanatory	  variables	  were	  checked	  for	  multicollinearity	  
using	  PROC	  CORR	  and	  spearman	  correlation	  coefficients	  were	  calculated.	  None	  of	  the	  correlations	  
appeared	  to	  be	  large,	  indicating	  that	  multicollinearity	  was	  not	  an	  issue	  with	  this	  model.	  	  Deviance	  and	  
Pearson	  goodness	  of	  fit	  statistics	  for	  the	  multinomial	  logistic	  regression	  residuals	  were	  tested.	  Deviance	  
produced	  a	  ratio	  of	  value	  to	  degrees	  of	  freedom	  of	  0.8499	  and	  a	  p-­‐value	  of	  0.8896.	  Pearson	  produced	  a	  
ratio	  of	  0.7898	  and	  a	  p-­‐value	  of	  0.962.	  	  Since	  both	  of	  these	  ratios	  were	  close	  to	  1,	  there	  was	  no	  
indication	  of	  sever	  under-­‐dispersion	  or	  over-­‐dispersion.	  	  
Binary	  logistic	  regression	  was	  carried	  out	  to	  model	  the	  probability	  of	  undergoing	  hormone	  
therapy,	  yes	  or	  no.	  A	  similar	  approach	  to	  the	  surgery	  analysis	  was	  employed	  considering	  potential	  
predictors	  to	  be	  univariate	  p-­‐values	  that	  were	  less	  than	  0.2	  and	  then	  eliminating	  predictors	  with	  the	  
largest	  p-­‐value	  one	  at	  a	  time.	  Again	  a	  priori	  interactions	  with	  age	  were	  also	  tested.	  Results	  included	  the	  
type	  3	  analysis	  of	  effects	  p-­‐values,	  odds	  ratio	  estimates	  and	  95%	  confidence	  intervals.	  	  Assumptions	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were	  checked	  using	  the	  lackfit	  option	  in	  PROC	  LOGISTIC	  which	  produced	  the	  Hosmer	  and	  Lemeshow	  
Goodness-­‐of-­‐fit	  test.	  	  The	  chi-­‐square	  test	  statistic	  is	  9.7475	  with	  9	  degrees	  of	  freedom,	  and	  the	  p-­‐value	  
was	  0.3713	  which	  indicated	  an	  adequate	  fit.	  Deviance	  and	  Pearson	  goodness	  of	  fit	  statistics	  for	  the	  
model	  residuals	  were	  tested.	  Deviance	  produced	  a	  ratio	  of	  value	  to	  degrees	  of	  freedom	  of	  1.4082	  and	  a	  
p-­‐value	  of	  0.1693.	  Pearson	  produced	  a	  ratio	  of	  1.3286	  and	  a	  p-­‐value	  of	  0.2081.	  	  Since	  both	  of	  these	  
ratios	  were	  close	  to	  1,	  there	  was	  no	  indication	  of	  sever	  under-­‐dispersion	  or	  over-­‐dispersion.	  Residual	  
diagnostic	  plots	  were	  produced	  to	  examine	  the	  standardized	  Pearson	  residual	  values,	  cook’s	  distance,	  
and	  leverage.	  No	  observations	  were	  found	  to	  have	  an	  extreme	  impact	  on	  the	  fit	  of	  the	  model.	  
Initial	  survival	  analyses	  were	  conducted	  to	  model	  time	  until	  death	  from	  breast	  cancer.	  DCIS	  has	  
a	  relatively	  low	  death	  rate	  and	  in	  this	  cohort	  there	  were	  only	  7	  deaths	  (2.3%).	  PROC	  LIFETEST	  was	  used	  
















By	  examining	  the	  frequency	  of	  surgical	  choice,	  we	  saw	  that	  bilateral	  risk	  reduction	  mastectomy	  
appeared	  to	  be	  used	  more	  widely	  in	  women	  who	  were	  <50	  years	  of	  age	  (61.5%)	  while	  breast	  conserving	  
surgery	  was	  used	  more	  in	  women	  over	  65	  years	  (28.7%)	  compared	  to	  20.5%	  for	  unilateral	  mastectomy	  
and	  10%	  for	  BRRM.	  	  Age	  at	  diagnosis,	  education,	  year,	  insurance,	  tumor	  size,	  multicentric	  disease,	  
menopausal	  status,	  and	  hormone	  receptor	  status	  were	  potential	  predictors	  for	  the	  model	  (p<.2).	  	  These	  
were	  factors	  likely	  to	  be	  associated	  with	  a	  woman’s	  surgical	  choice,	  for	  example,	  the	  likeliness	  of	  a	  
particular	  surgical	  choice	  could	  vary	  depending	  on	  how	  old	  she	  is	  or	  what	  year	  she	  was	  diagnosed.	  
	  
Table 1a: Demographics and Clinical Characteristics of Women with Stage 0 DCIS Disease  
by Surgical Choice 
 















Age at Diagnosis 
<50 
N 113 52 37 24 
0.0037 
Col 
(%) 37.05 29.21 42.05 61.54 
50-64 
N 119 75 33 11 
Col 
(%) 39.02 42.13 37.50 28.21 
>=65 
N 73 51 18 4 
Col 
(%) 23.93 28.65 20.45 10.26 
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53.77 57.30 46.59 53.85 
Hispanic 
N 67 40 20 7 
Col 
(%) 
21.97 22.47 22.73 17.95 
Other 
N 74 36 27 11 
Col 
(%) 








45.57 43.82 55.68 30.77 
More Than 
High School 
N 166 100 39 27 
Col 
(%) 
54.43 56.18 44.32 69.23 
Insurance 
Other 




1.31 1.12 0 5.13 
Managed 
N 172 93 50 29 
Col 
(%) 56.39 52.25 56.82 74.36 
Medicare 
N 81 56 21 4 
Col 
(%) 26.56 31.46 23.86 10.26 
Medicaid 
N 48 27 17 4 
Col 
(%) 15.74 15.17 19.32 10.26 
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N 125 57 42 26 
0.0012 
Col 
(%) 40.98 32.02 47.73 66.67 
Post 
N 179 121 46 12 
Col 
(%) 58.69 67.98 52.27 30.77 
Conflict 
N 1 0 0 1 
Col 
(%) 0.33 0 0 2.56 
Hormone Receptor 
Unknown 
N 146 73 52 21 
0.0591 
Col 
(%) 47.87 41.01 59.09 53.85 
Negative 
N 31 20 6 5 
Col 
(%) 10.16 11.24 6.82 12.82 
Positive 
N 128 85 30 13 
Col 
(%) 41.97 47.75 34.09 33.33 
Year 
No 
N 121 69 41 11 
0.1421 
Col 
(%) 39.67 38.76 46.59 28.21 
Yes 
N 184 109 47 28 
Col 
(%) 60.33 61.24 53.41 71.79 
Grade 
Unknown 
N 128 75 38 15 
0.2340 
Col 
(%) 41.97 42.13 43.18 38.46 
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N 29 21 6 2 
Col 
(%) 9.51 11.80 6.82 5.13 
Intermediate 
N 80 50 22 8 
Col 
(%) 26.23 28.09 25.00 20.51 
High 
N 68 32 22 14 
Col 
(%) 22.30 17.98 25.00 35.90 
Tumor Size 
Unknown 
N 146 73 52 21 
0.0591 
Col 
(%) 47.87 41.01 59.09 53.85 
Negative 
N 31 20 6 5 
Col 
(%) 10.16 11.24 6.82 12.82 
Positive 
N 128 85 30 13 
Col 
(%) 41.97 47.75 34.09 33.33 
Multicentric Disease 
No 
N 246 167 51 28 
<0.0001 
Col 
(%) 80.66 93.82 57.95 71.79 
Yes 
N 59 11 37 11 
Col 
(%) 19.34 6.18 42.05 28.21 
Footnote	  1:	  P-­‐Values	  obtained	  from	  univariate	  multinomial	  logistic	  regression	  with	  
surgical	  choice	  as	  the	  response	  variable.	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Modeling	  
Table	  1b	  summarizes	  the	  results	  from	  the	  final	  multinomial	  logistic	  regression	  model	  with	  
surgical	  choice	  as	  the	  response.	  Significant	  variables	  included	  age	  at	  diagnosis	  (p=0.0076),	  year	  of	  
diagnosis	  (p=0.0228),	  tumor	  size	  (p=0.0004),	  multicentric	  disease	  (p<0.0001),	  and	  hormone	  receptor	  




Table 1b: Predictors of Surgical Choice in Women with DCIS, N=305 
 














< 50 Reference Group Reference Group 
50-64 3.26 (1.38, 7.68) 2.44 (0.99, 5.98) 
>=65 6.64 (2.02, 21.84) 3.43 (0.99, 11.83) 
Year 0.0228 
2005-2012 Reference Group Reference Group 
1997-2004 3.91 (1.48, 10.33) 2.51 (0.94, 6.71) 
Tumor Size 0.0004 
>=2 Reference Group Reference Group 
< 2 3.35 (1.24, 9.05) 0.67 (0.25, 1.77) 
Unknown 1.73 (0.56, 5.35) 0.39 (0.13, 1.19) 
Multicentric 
Disease <0.0001 
Yes Reference Group Reference Group 





Positive Reference Group Reference Group 
Negative 0.69 (0.18, 2.62) 0.43 (0.10, 1.80) 
Unknown 0.189 (0.07, 0.50) 0.75 (0.28, 2.01) 
	  
When	  comparing	  breast	  conserving	  surgery	  to	  bilateral	  risk	  reduction	  mastectomy,	  several	  
significant	  associations	  were	  found.	  	  In	  this	  multivariable	  model	  it	  was	  estimated	  that	  patients	  who	  were	  
50-­‐64	  years	  of	  age	  at	  diagnosis	  were	  3.26	  times	  more	  likely	  to	  choose	  breast	  conserving	  surgery	  over	  
bilateral	  risk	  reduction	  mastectomy	  than	  patients	  who	  were	  less	  than	  50	  years	  old	  (95%	  CI	  1.38-­‐7.68).	  
This	  effect	  is	  even	  larger	  when	  comparing	  patients	  65	  years	  and	  older	  who	  were	  6.64	  times	  more	  likely	  
to	  choose	  breast	  conserving	  surgery	  as	  opposed	  to	  bilateral	  mastectomy	  than	  younger	  women.	  Patients	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who	  were	  diagnosed	  between	  1997	  and	  2004	  were	  3.91	  times	  more	  likely	  to	  choose	  a	  breast	  conserving	  
surgery	  over	  bilateral	  risk	  reduction	  mastectomy	  than	  patients	  who	  were	  diagnosed	  between	  2005	  and	  
2012.	  	  Those	  with	  small	  tumors	  (less	  than	  2cm)	  were	  estimated	  to	  be	  3.35	  times	  more	  likely	  to	  choose	  
breast	  conserving	  surgery	  over	  bilateral	  mastectomy	  than	  those	  with	  larger	  tumors	  (95%	  CI	  1.24-­‐9.05).	  
Patients	  without	  a	  multicentric	  disease	  were	  estimated	  to	  be	  6.69	  times	  more	  likely	  to	  choose	  breast	  
conserving	  surgery	  over	  bilateral	  mastectomy	  than	  patients	  with	  a	  multicentric	  disease.	  Also,	  those	  with	  
a	  positive	  hormone	  receptor	  status	  were	  estimated	  to	  be	  5.28	  (1/0.189)	  times	  more	  likely	  to	  choose	  
breast	  conserving	  surgery	  over	  bilateral	  mastectomy	  than	  patients	  with	  unknown	  hormone	  receptor	  
status.	  	  When	  comparing	  the	  likeliness	  of	  choosing	  unilateral	  mastectomy	  to	  bilateral	  risk	  reduction	  
mastectomy	  the	  differences	  weren’t	  significant.	  	  	  
Hormone	  Therapy	  
Descriptive	  Statics	  
The	  sample	  size	  was	  reduced	  to	  243	  to	  only	  include	  patients	  who	  had	  breast	  conserving	  surgery	  
or	  unilateral	  mastectomy,	  as	  these	  surgeries	  can	  be	  followed	  up	  with	  additional	  treatment.	  	  The	  sample	  
was	  also	  reduced	  to	  patients	  who	  had	  at	  least	  270	  days	  of	  follow	  up	  to	  account	  for	  the	  time	  necessary	  
for	  adjuvant	  treatment.	  It	  is	  interesting	  that	  more	  women	  with	  a	  multicentric	  disease	  choose	  not	  to	  
undergo	  hormone	  therapy	  than	  to	  have	  this	  additional	  therapy	  (22.4%	  vs.	  12.7%).	  Also,	  more	  women	  
who	  chose	  unilateral	  mastectomy	  choose	  not	  to	  undergo	  hormone	  therapy	  as	  additional	  treatment	  
(40.88%	  vs.	  22.88%).	  Age,	  grade,	  tumor	  size,	  multicentric	  disease,	  hormone	  receptor	  status,	  radiation	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Table 2a: Demographics and Clinical Characteristics of Women with Stage 0 DCIS  and Breast Conserving Surgery 
or Unilateral Mastectomyby Receipt of Hormone Therapy 
 








Age at Diagnosis 
<50 
N 76 38 38 
0.1525 
Col 
(%) 31.28 32.20 30.40 
50-64 
N 100 54 46 
Col 
(%) 41.15 45.76 36.80 
>=65 
N 67 26 41 
Col 
(%) 27.57 22.03 32.80 
Race 
Caucasian 
N 135 66 69 
0.4131 
Col 
(%) 55.56 55.93 55.20 
Hispanic 
N 51 28 23 
Col 
(%) 20.99 23.73 18.40 
Other 
N 57 24 33 
Col 




N 117 59 58 
0.5748 
Col 
(%) 48.15 50.00 46.40 
More Than 
High School 
N 126 59 67 
Col 
(%) 51.85 50.00 53.60 
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N 2 1 1 
0.3530 
Col 
(%) 0.82 0.85 0.80 
Managed 
N 130 63 67 
Col 
(%) 53.50 53.39 53.60 
Medicare 
N 75 32 43 
Col 
(%) 30.86 27.12 34.40 
Medicaid 
N 36 22 14 
Col 
(%) 14.81 18.64 11.20 
Menopausal Status 
Pre 
N 85 42 43 
0.8454 
Col 
(%) 34.98 35.59 34.40 
Post 
N 158 76 82 
(%) 65.02 64.41 65.60 
Hormone Receptor 
Unknown 
N 116 58 58 
0.0033 
Col 
(%) 47.74 49.15 46.40 
Negative 
N 23 2 21 
Col 
(%) 9.47 1.69 16.80 
Positive 
N 104 58 46 
Col 
(%) 42.80 49.15 36.80 
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N 104 54 50 
0.3645 
Col 
(%) 42.80 45.76 40.00 
2005-2012 
N 139 64 75 
Col 
(%) 57.20 54.24 60.00 
Grade 
Unknown 
N 108 55 53 
0.0345 
Col 
(%) 44.44 46.61 42.40 
Low 
N 22 9 13 
Col 
(%) 9.05 7.63 10.40 
Intermediate 
N 66 39 27 
Col 
(%) 27.16 33.05 21.60 
High 
N 47 15 32 
Col 
(%) 19.34 12.71 25.60 
Tumor Size 
Unknown 
N 43 22 21 
0.0689 
Col 
(%) 17.70 18.64 16.80 
<2 
N 143 76 67 
Col 
(%) 58.85 64.41 53.60 
>=2 
N 57 20 37 
Col 
(%) 23.46 16.95 29.60 
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N 200 103 97 
0.0505 
Col 
(%) 82.30 87.29 77.60 
Yes 
N 43 15 28 
Col 
(%) 17.70 12.71 22.40 
Surgical Margins 
Unknown 
N 125 44 81 
<0.0001 
Col 
(%) 51.44 37.29 64.80 
Negative 
N 100 60 40 
Col 
(%) 41.15 50.85 32.00 
Positive 
N 18 14 4 
Col 





N 165 91 74 
0.0031 
Col 
(%) 67.90 77.12 59.20 
Unilateral 
Mastectomy 
N 78 27 51 
Col 
(%) 32.10 22.88 40.80 
Radiation Therapy 
Yes 
N 120 75 45 
<0.0001 
(%) 49.38 63.56 36.00 
No 
Col 
N 123 43 80 
(%) 50.62 36.44 64.00 
Footnote	  1:	  P-­‐Values	  obtained	  from	  univariate	  logistic	  regression	  with	  hormone	  therapy	  as	  the	  response	  variable.	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Modeling	  
Table	  2b	  summarizes	  the	  results	  from	  modeling	  the	  probability	  of	  undergoing	  hormone	  therapy.	  
The	  final	  model	  included	  hormone	  receptor	  status	  and	  the	  interaction	  between	  radiation	  therapy	  and	  
age	  at	  diagnosis	  as	  explanatory	  variables.	  
	  
Table 2b: Predictors of Receipt of Hormone Therapy for Women with DCIS and Breast Conserving Surgery or 
Unilateral Mastectomy 
 







Negative Reference Group 
Positive 15.22 (3.25, 71.24) 
Unknown 12.07 (2.60, 56.05) 
Radiation 





<50 Reference Group 
50-64 3.35 (1.25, 8.99) 
>=65 0.99 (0.33, 2.99) 
Yes RT 
<50 Reference Group 
50-64 0.65 (0.26, 1.63) 





The	  results	  showed	  that	  in	  this	  multivariable	  model	  a	  woman	  with	  a	  positive	  hormone	  receptor	  
status	  was	  estimated	  to	  be	  15.22	  times	  more	  likely	  to	  undergo	  hormone	  therapy	  than	  a	  woman	  with	  a	  
negative	  hormone	  receptor	  status	  (95%	  CI	  3.25-­‐71.24).	  Additionally	  a	  woman	  with	  an	  unknown	  
hormone	  receptor	  status	  	  was	  likely	  to	  undergo	  hormone	  therapy	  than	  a	  patient	  with	  negative	  hormone	  
receptor	  status	  (OR=12.07,	  95%	  CI	  2.60-­‐56.05).	  	  
The	  interaction	  between	  age	  and	  radiation	  demonstrated	  that	  the	  relationship	  between	  age	  and	  
likeliness	  of	  undergoing	  hormone	  therapy	  varies	  by	  receipt	  of	  radiation.	  For	  patients	  who	  haven’t	  had	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radiation	  therapy,	  the	  estimated	  odds	  of	  undergoing	  hormone	  therapy	  were	  3.35	  times	  higher	  for	  those	  




Figure	  1	  shows	  an	  overall	  survival	  probability	  plot	  for	  stratified	  by	  choice	  of	  surgery,	  bilateral	  risk	  
reduction	  mastectomy	  or	  not.	  
Figure 1: Survival Probability Plot by Choice of Bilateral Risk Reduction  
Mastectomy for Women with Stage 0 DCIS Disease (N=305) 
	  
	  
There	  was	  not	  a	  significant	  difference	  between	  the	  overall	  survival	  of	  women	  who	  received	  
BRRM	  and	  those	  who	  did	  not	  (p-­‐value=.5406).	  As	  there	  was	  no	  significant	  effect	  of	  whether	  or	  not	  a	  
woman	  received	  a	  bilateral	  risk	  reduction	  mastectomy,	  it	  was	  not	  necessary	  to	  move	  on	  perform	  
regression	  analysis	  of	  the	  survival	  data	  based	  on	  the	  Cox	  proportional	  hazards	  modelcontrolling	  for	  
other	  covariates.	  Table	  3	  shows	  that	  only	  7	  women	  (2.3%)	  died	  from	  breast	  cancer.	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N 298 173 87 38 
Col 
(%) 97.70 97.19 98.86 97.44 
Dead 
N 7 5 1 1 
Col 
















	   23	  
Conclusion	  
	  
This	  analysis	  demonstrated	  that	  age	  at	  diagnosis,	  year,	  tumor	  size,	  presence	  of	  multicentric	  
disease,	  and	  hormone	  receptor	  status	  were	  significant	  factors	  in	  predicting	  DCIS	  woman’s	  likeliness	  
surgical	  choice	  for	  breast	  conserving	  surgery	  compared	  to	  bilateral	  risk	  reduction	  mastectomy.	  	  It	  was	  
shown	  that	  older	  women	  tend	  to	  be	  more	  likely	  to	  choose	  breast	  conserving	  surgery	  than	  older	  women.	  
It	  is	  logical	  that	  older	  women	  were	  not	  going	  to	  want	  to	  undergo	  an	  extreme	  surgical	  operation	  either	  
due	  to	  their	  health	  or	  desire	  to	  fight	  the	  disease.	  There	  was	  a	  similar	  relationship	  with	  women	  who	  were	  
diagnosed	  between	  1997	  and	  2004,	  those	  with	  small	  tumors	  (<2cm),	  those	  without	  multicentric	  disease,	  
and	  those	  with	  a	  positive	  hormone	  receptor	  status.	  Breast	  cancer	  awareness	  has	  increased	  dramatically	  
in	  recent	  years.	  Because	  of	  this,	  women	  diagnosed	  more	  recently	  appear	  to	  be	  more	  aware	  of	  their	  
options	  so	  it’s	  logical	  they	  were	  more	  likely	  to	  choose	  an	  extreme	  surgery.	  Women	  with	  larger	  tumors	  
were	  also	  more	  willing	  to	  undergo	  bilateral	  risk	  reduction	  mastectomy.	  If	  a	  woman	  has	  more	  than	  one	  
tumor	  (multicentric	  disease),	  then	  it	  makes	  sense	  that	  she	  would	  be	  more	  likely	  to	  take	  aggressive	  risk	  
reduction	  actions.	  Women	  with	  unknown	  hormone	  receptor	  status	  may	  also	  want	  a	  bilateral	  
mastectomy	  because	  they	  may	  not	  be	  candidates	  for	  hormone	  therapy	  after	  BCS	  or	  ULM,	  unfortunately	  
the	  same	  could	  not	  be	  detected	  in	  the	  hormone	  negative	  women.	  When	  comparing	  likeliness	  of	  
choosing	  a	  unilateral	  mastectomy	  to	  a	  bilateral	  risk	  reduction	  mastectomy,	  there	  were	  no	  significant	  
comparisons.	  Choosing	  between	  a	  surgery	  that	  is	  less	  invasive	  and	  where	  the	  woman	  keeps	  her	  breasts	  
as	  opposed	  to	  an	  extreme	  surgery	  where	  both	  breasts	  were	  removed	  is	  a	  drastic	  difference.	  However	  
when	  a	  woman	  is	  choosing	  between	  invasive	  surgery	  where	  she	  loses	  just	  one	  breast	  or	  more	  invasive	  
surgery	  where	  she	  loses	  two,	  the	  difference	  is	  not	  quite	  as	  extreme.	  Therefore	  it	  seems	  reasonable	  that	  
only	  differences	  the	  between	  BCS	  and	  BRRM	  were	  significant.	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Of	  the	  women	  who	  chose	  to	  undergo	  breast	  conserving	  surgery	  or	  a	  unilateral	  mastectomy,	  
hormone	  receptor	  status	  and	  the	  interaction	  between	  age	  and	  radiation	  were	  significant	  predictors	  of	  
receipt	  of	  hormone	  therapy.	  A	  patient	  with	  a	  positive	  or	  unknown	  hormone	  receptor	  status	  was	  much	  
more	  likely	  to	  undergo	  hormone	  therapy	  than	  a	  patient	  with	  negative	  hormone	  receptor	  status.	  This	  
result	  was	  not	  surprising,	  seeing	  as	  the	  hormone	  therapy	  is	  proven	  more	  effective	  for	  those	  with	  
positive	  hormone	  receptors.	  	  It	  was	  interesting	  to	  note	  that	  the	  relationship	  between	  age	  and	  likeliness	  
of	  undergoing	  hormone	  therapy	  varies	  between	  patients	  that	  have	  had	  radiation	  therapy	  and	  those	  who	  
haven’t.	  It	  was	  found	  that	  the	  estimated	  odds	  of	  undergoing	  hormone	  therapy	  were	  higher	  for	  patients	  
who	  were	  in	  the	  mid-­‐age	  range	  and	  who	  haven’t	  had	  radiation	  therapy.	  This	  might	  be	  because	  women	  
who	  are	  slightly	  older	  may	  be	  better	  positioned	  hormonally	  to	  try	  hormone	  therapy,	  but	  women	  who	  
were	  older	  are	  not	  willing	  to	  undergo	  hormone	  therapy	  due	  to	  side	  effects	  or	  personal	  aversions.	  
Due	  to	  a	  small	  proportion	  of	  cases	  that	  resulted	  in	  death,	  no	  significant	  conclusions	  could	  be	  
formed	  in	  examining	  the	  impact	  bilateral	  risk	  reduction	  mastectomies	  have	  on	  a	  patient’s	  survival	  from	  
breast	  cancer.	  	  DCIS	  is	  a	  noninvasive,	  stage	  0	  cancer,	  and	  treatment	  can	  prevent	  it	  from	  becoming	  a	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Further	  Research	  
	  
Further	  research	  could	  be	  conducted	  in	  the	  area	  of	  survival	  analysis.	  DCIS	  has	  a	  relatively	  low	  
death	  rate	  compared	  to	  other	  forms	  of	  breast	  cancer.	  There	  is	  however	  a	  higher	  risk	  of	  developing	  
subsequent	  cancer	  in	  the	  other	  breast.	  	  Therefore	  disease	  free	  survival	  in	  which	  time	  until	  occurrence	  of	  
subsequent	  breast	  cancer	  could	  be	  explored	  in	  addition	  to	  overall	  survival.	  This	  would	  examine	  the	  
effectiveness	  of	  bilateral	  risk	  reduction	  mastectomies	  in	  preventing	  subsequent	  breast	  cancer.	  It	  is	  
important	  to	  note	  however	  that	  disease	  free	  survival	  in	  breast	  cancer	  is	  complicated	  due	  to	  high	  lost	  to	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Appendix	  
 
The following SAS code was used to carry out this analysis: 
(Please note that the data for this analysis is confidential and is on file with Rebecca Ottesen) 
 
 
***SENIOR PROJECT: CREATING DATA SETS; 
libname der 'C:\Users\Lauren\Dropbox\SrProj\NEW data\Derived'; 
libname raw 'C:\Users\Lauren\Dropbox\SrProj\NEW data\Raw'; 
libname myfmts 'C:\Users\Lauren\Dropbox\SrProj\NEW data'; 
options fmtsearch=(der.ddformats raw.formats myfmts); run; 
 
/* viewing formats 
proc format library=der.ddformats fmtlib;run; 
proc format library=raw.formats fmtlib;run; */ 
 
*Create formats for grouping predictor variables; 
proc format library=myfmts; 
value agegroup 
20-<50 = '<50' 
50-<65 = '50-64' 
65-100 = '>=65'; 
value racegroup 
1 = 'Caucasian Non-Hispanic' 
2 = 'Caucasian Hispanic' 
3, 10 = 'African American and other Non-Hispanic' 
5 = 'Asian, Pac Isl Non-Hispanic'; 
value racegroupp 
1 = 'Caucasian Non-Hispanic' 
2 = 'Hispanic' 
3, 5, 10 = 'Other Non-Hispanic'; 
value racegroup_w 
1 = 'Caucasian Non-Hispanic' 
2, 3, 5, 10 = 'Other'; 
value edugroup 
-1-3 = 'High School or Less' 





2, 3, 5, 5.5, 5.75 = 'Medicare' 
4 = 'Medicaid' 
1 = 'Managed' 
-1, 6, 7, 0 = 'Other'; 
value tumorgroup 
0-2 = '<2' 
2-11 = '>=2' 
-1 = 'Unknown'; 
value margingroup 
-1 = 'Unknown' 
0 = 'Negative' 
3, 4 = 'Positive'; 
value $outgroup 
'BCS' = 'No BRRM' 
'ULM' = 'No BRRM' 
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'BRRM' = 'BRRM'; 
value adjTX 
2, 99 = 'No' 





*Merge solid tumor stage and clinical characteristics data sets; 
data stage_clinical; 
merge raw.solid_tumor_stage der.clinical_characteristics; 
by pid dxid tumorid; 
run; 
 
*Merge above with patient characteristcs to create the cohort; 
data cohort; 
merge stage_clinical der.patient_characteristics; 
by pid dxid; 
if histology ^= 2 then delete; 
if fu90 ^= 1 then delete; 





**BREAST CONSERVING SURGERY PATIENTS; 
 
*Find BCS patients; 




*Match to those in cohort; 
data bcs_dcis; 
merge bcs(in=inbcs keep=pid dxid tumorid dsgroup) cohort(in=incohort); 
by pid dxid tumorid; 
if inbcs and incohort; 
surggroup="BCS"; 
run; 





*Find Mastectomy patients; 





*Match to those in cohort; 
data mast_dcis; 
merge mast(in=inmast keep=pid dxid tumorid dsgroup) cohort(in=incohort); 
by pid dxid tumorid; 
if inmast and incohort; 
run; 
*127 patients (with 90 day followup); 
	   29	  
 
*Separate Mastectomy and Radiation Therapy patients from Treatment data set; 
data treatment radiation; set raw.treatment; 
if txcat=11 and proctype in(11 12 14 15 16) then output treatment; 
else if txcat=16 and proctype=1 then output treatment; 
else if txcat=10 and indication in(1, 2, 4) then output radiation; 
run; 
 
*Find Contralateral Mastectomy patients; 
data rawtrt_sts; 
merge treatment(in=intrt) raw.solid_tumor_stage; 
by pid dxid; 
if intrt then do; 






*Merge Contralateral Mastectomy patients with all Mastectomy patients; 
data mast2; 
merge rawtrt_sts(keep= pid dxid flag2) mast_dcis(in=inmast); 




**MERGE PATIENTS WITH OTHER DATA SETS TO OBTAIN PREDICTOR VARIABLES; 
 
*Merge bcs with study accession by pid; 
data bcs_dcis2; 





*Merge mast with study accession by pid; 
data mast_dcis2; 





*Merge bcs with adjuvant drug therapy by pid, dxid; 
data bcs_dcis3; 
merge bcs_dcis2(in=inbcs) der.adjuvant_drug_therapy; 




*Merge mast with adjuvant drug therapy by pid, dxid; 
data mast_dcis3; 
merge mast_dcis2(in=inmast) der.adjuvant_drug_therapy; 
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*Merge bcs with surgical information and breast diagnosis by pid, dxid, 
tumorid; 
data bcs_dcis4; 
merge bcs_dcis3(in=inbcs) der.surgical_information raw.breast_diagnosis; 




*Merge mast with surgical information and breastdx by pid, dxid, tumorid; 
data mast_dcis4; 
merge mast_dcis3(in=inmast) der.surgical_information raw.breast_diagnosis; 





**CREATE DATA SET FOR OUTCOME ANALYSIS; 
 
data der.allpatients; 
set bcs_dcis4(in=inbcs) mast_dcis4; 
length outcome $4; 
*Determine outcome; 
if inbcs then outcome="BCS"; 
else if flag2="contralateral" then outcome="BRRM"; 
else if flag2=" " then outcome="ULM"; 
*Create year to use as a predictor variable; 
year=year(tumordxdt); 
if dcispathtumsize= . then dcispathtumsize=-1; 
*Assign user created formats to variables; 
format agedx agegroup.  





*Keep only variables used in analysis; 
keep pid agedx race_eth edustat year dcishistogrd insurance dcispathtumsize 
dcismulcent menopause HR outcome fu90 fu270 adjtxgroup; 
run; 
*305 patients (90 day followup); 
 
 
*CREATE DATA SET FOR HORMONE THERAPY ANALYSIS; 
 
*Merge radiation therapy patients with solid tumor stage data set; 
data radiation2;  
merge radiation(in=inr) raw.solid_tumor_stage; 




*Merge above data with patient characteristics; 
data radiation3; 
merge radiation2(in=inr) der.patient_characteristics; 
by pid; 
if inr; 
if side^=finallat then delete; 
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run; 
 
*Match radiation therapy patients to those in cohort; 
data radiation_cohort; 
merge radiation3(in=inr) cohort(in=inc); 
by pid; 





*Merge with all patients data set to create final data set for hormone 
therapy analysis; 
proc sort data=der.allpatients; by pid; run; 
data der.hormone;  
merge der.allpatients(in=inall) radiation_cohort; 
by pid; 
if inall; 
*Eliminate BRRM patients; 
if outcome in('BCS','ULM'); 
*Use only patients with 270 day follow-up rule; 
where fu270=1; 
if txcat=10 then radiation='Yes'; 
else radiation='No'; 
if surgmargin=. then surgmargin=-1; 
*Assign format to adjuvant treatment group variable; 
format adjtxgroup adjtx. 
surgmargin margingroup.; 
if dcispathtumsize= . then dcispathtumsize=-1; 
*Keep only variables used in analysis; 
keep pid agedx race_eth edustat year dcishistogrd insurance dcispathtumsize 
dcismulcent menopause HR outcome surgmargin radiation adjtxgroup; 
run; 
*243 Patients (270 day followup); 
 
 
*CREATE DATA SET FOR SURVIVAL ANALYSIS; 
proc contents data=bcs_dcis4; run; 




set bcs_dcis4(in=inbcs) mast_dcis4; 
length outcome $4 BRRM $3.; 
*Determine outcome; 
if inbcs then outcome="BCS"; 
else if flag2="contralateral" then outcome="BRRM"; 
else if flag2=" " then outcome="ULM"; 
if outcome='BCS' then BRRM='No'; 
else if outcome='ULM' then BRRM='No'; 
else if outcome='BRRM' then BRRM='Yes'; 




*Assign user created formats to variables; 
format agedx agegroup.  
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*Keep only variables used in analysis; 
keep pid agedx race_eth edustat year dcishistogrd insurance dcispathtumsize 
dcismulcent menopause HR outcome fu90 fu270 adjtxgroup event osdt ossource 
BRRM time time_yr; 
run; 
 













































proc freq data=der.allpatients; 




*HORMONE RECEPTOR STATUS; 





**UNIVARIATE RELATIONSHIPS BETWEEN POTENTIAL PREDICTORS AND OUTCOME; 
 
*AGE; 




*p-value = 0.0037; 
 
*RACE; 




*p-value = 0.3448; 
 
*EDUCATION; 




*p-value = 0.0283; 
 
*YEAR; 




*p-value = 0.1421; 
 
*GRADE; 




*p-value = 0.2340; 
 
*INSURANCE; 




*p-value = 0.0758; 
 
*TUMOR SIZE; 
proc logistic data=der.allpatients; 
class dcispathtumsize/param=ref missing; 
model outcome=dcispathtumsize/link=glogit; 
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run; 
*p-value = 0.0002; 
 
*MULTICENTRIC DISEASE; 




*p-value < 0.0001; 
 
*MENOPAUSAL STATUS; 




*p-value = 0.0012; 
 
*HORMONE RECEPTOR STATUS; 




*p-value = 0.0591; 
 
 
**NARROWED DOWN POTENTIAL PREDICTORS (p-value<.2): 
Age, Education, Year, Insurance, Tumor Size, Multicentric Disease, Menopausal 
Status, Hormone Receptor Status; 
 
 
**MODELING WITH POTENTIAL PREDICTORS; 
 
*Model with narrowed down potential predictors; 
proc logistic data=der.allpatients; 
class agedx edustat year insurance dcispathtumsize dcismulcent menopause 
HR/param=ref missing; 





proc logistic data=der.allpatients; 
class agedx edustat year dcispathtumsize dcismulcent menopause HR/param=ref 
missing; 




*Drop Menopausal Status; 
proc logistic data=der.allpatients; 
class agedx edustat year dcispathtumsize dcismulcent HR/param=ref missing; 




proc logistic data=der.allpatients; 
class agedx year dcispathtumsize dcismulcent HR/param=ref missing; 
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**MODELING WITH INTERACTIONS; 
 
*Interaction of Age and Race; 
proc logistic data=der.allpatients; 
class agedx year dcispathtumsize HR dcismulcent/param=ref missing; 




*Take out Race, Interaction between Age and Year; 
proc logistic data=der.allpatients; 
class agedx year dcispathtumsize HR dcismulcent/param=ref missing; 




*Interaction between Age and Tumor Size; 
proc logistic data=der.allpatients; 
class agedx year dcispathtumsize HR dcismulcent/param=ref missing; 




*Interaction between Age and Hormone Receptor Status; 
proc logistic data=der.allpatients; 
class agedx dcispathtumsize HR dcismulcent/param=ref missing; 
model outcome=agedx dcispathtumsize HR dcismulcent agedx*HR/link=glogit; 
run; 
 
*Interaction between Age and Multicentric Disease; 
proc logistic data=der.allpatients; 
class agedx dcispathtumsize HR dcismulcent/param=ref missing; 




*Interaction between Age and Education; 
proc logistic data=der.allpatients; 
class agedx edustat dcispathtumsize HR dcismulcent/param=ref missing; 





**BEST MODEL: AGE, YEAR, TUMOR SIZE, MULTICENTRIC DISEASE, HORMONE RECEPTOR 
STATUS; 
proc logistic data=der.allpatients; 
class agedx(ref='<50') year(ref='2005-2012') dcispathtumsize(ref='>=2') 
dcismulcent HR(ref='Negative')/param=ref; 
model outcome(ref='BRRM')=agedx year dcispathtumsize dcismulcent 
HR/link=glogit aggregate scale=D influence rsquare stb iplots; 
run; 
 
	   36	  
**CHECK OTHER MODEL ASSUMPTIONS; 
ods graphics on; 
proc corr data=der.allpatients spearman; 
var agedx year dcispathtumsize dcismulcent HR; 
run; 
proc genmod data=der.allpatients plots=(stdreschi reschi leverage dobs); 
class outcome agedx year dcispathtumsize dcismulcent HR/ param=ref; 
model outcome=agedx year dcispathtumsize dcismulcent HR/ link=cumcll 
dist=multinomial; 
output out=resids reschi=pearson stdreschi=sdtpearson leverage=lev 
cooksd=infl; 
run; 
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*HORMONE RECEPTOR STATUS; 




























*p-value = 0.1525; 
 
*RACE; 




*p-value = 0.4131; 
 
*EDUCATION;  




*p-value = 0.5748; 
 
*YEAR; 
proc logistic data=der.hormone; 
class year/param=ref; 
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model adjtxgroup=year; 
run; 
*p-value = 0.3645; 
 
*GRADE; 




*p-value = 0.0345; 
 
*INSURANCE; 




*p-value = 0.3530; 
 
*TUMOR SIZE; 




*p-value = 0.0689; 
 
*MULTICENTRIC DIEASE;  




*p-value = 0.0505; 
 
*MENOPAUSAL STATUS; 




*p-value = 0.8454; 
 
*HORMONE RECEPTOR STATUS; 




*p-value = 0.0033; 
 
*OUTCOME; 




*p-value = 0.0031; 
 
*SURGICAL MARGINS;  
proc logistic data=der.hormone; 
class surgmargin/param=ref; 
model adjtxgroup=surgmargin; 
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run; 
*p-value < 0.0001; 
 
*RADIATION THERAPY; 




*p-value < 0.0001; 
 
 
**NARROWED DOWN POTENTIAL PREDICTORS (p-value<.2): 




**MODELING WITH POTENTIAL PREDICTORS; 
 
*Model with narrowed down potential predictors; 
proc logistic data=der.hormone; 
class agedx dcishistogrd dcispathtumsize dcismulcent HR outcome surgmargin 
radiation/param=ref; 





proc logistic data=der.hormone; 
class agedx dcishistogrd dcispathtumsize dcismulcent HR outcome 
surgmargin/param=ref; 





proc logistic data=der.hormone; 
class agedx dcishistogrd dcispathtumsize dcismulcent HR surgmargin/param=ref; 




*Drop Tumor Size; 
proc logistic data=der.hormone; 
class agedx dcishistogrd dcismulcent HR surgmargin/param=ref; 
model adjtxgroup=agedx dcishistogrd dcismulcent HR surgmargin/lackfit; 
run; 
 
*Drop Multicentric Disease; 
proc logistic data=der.hormone; 
class agedx dcishistogrd HR surgmargin/param=ref; 




proc logistic data=der.hormone; 
class agedx HR surgmargin/param=ref; 
model adjtxgroup=agedx HR surgmargin/lackfit; 




proc logistic data=der.hormone; 
class HR surgmargin/param=ref; 




**INTERACTIONS WITH AGE; 
 
*Interaction between Age and HR; 
proc logistic data=der.hormone; 
class agedx HR surgmargin/param=ref; 
model adjtxgroup=agedx HR surgmargin agedx*HR/lackfit; 
run; 
 
*Interaction between Age and Surgical Margins; 
proc logistic data=der.hormone; 
class agedx HR surgmargin/param=ref; 
model adjtxgroup=agedx HR surgmargin agedx*surgmargin/lackfit; 
run; 
 
*Interaction between Age and Radiation without surgical margins; 
proc logistic data=der.hormone; 
class agedx HR radiation/param=ref; 
model adjtxgroup=agedx HR radiation agedx*radiation/lackfit; 
run; 
 
*Interaction between Age and Grade; 
proc logistic data=der.hormone; 
class agedx dcishistogrd dcispathtumsize HR surgmargin/param=ref; 




*Interaction between Age and Tumor Size; 
proc logistic data=der.hormone; 
class agedx dcishistogrd dcispathtumsize HR surgmargin/param=ref; 





**BEST MODEL: HORMONE RECEPTOR STATUS AND AGE-RADIATION INTERACTION; 
proc logistic data=der.hormone; 
class agedx(ref='<50') HR(ref='Negative') radiation/param=ref; 
model adjtxgroup(ref='No')=agedx HR radiation agedx*radiation/lackfit 
aggregate scale=D influence rsquare stb iplots; 
oddsratio agedx / diff=ref; 
oddsratio hr / diff=ref; 
run; 
 
**CHECK OTHER MODEL ASSUMPTIONS; 
ods graphics on; 
proc genmod data=der.hormone plots=(stdreschi reschi leverage dobs); 
class adjtxgroup agedx HR radiation/param=ref; 
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model adjtxgroup=agedx HR radiation agedx*radiation/link=logit dist=bin; 
output out=resids reschi=pearson stdreschi=stdpearson leverage=lev 
cooksd=infl; 
run; 
proc corr data=der.hormone spearman; 
var agedx HR; 
run; 
ods graphics off; 
 
 
***ANALYSIS FOR SURVIVAL; 
 




***outcome and all covariates; 
proc phreg data=der.survival plots(overlay)=survival; 
class outcome agedx race_eth edustat year dcishistogrd insurance 
dcispathtumsize dcismulcent menopause HR; 
model time_yr*event(0)=outcome agedx race_eth edustat year dcishistogrd 
insurance dcispathtumsize dcismulcent menopause HR; 
run; 
 
*remove HR, dcishistogrd, and year; 
proc phreg data=der.survival plots(overlay)=survival; 
class outcome agedx race_eth edustat insurance dcispathtumsize dcismulcent 
menopause; 
model time_yr*event(0)=outcome agedx race_eth edustat insurance 




*remove tumor size, insurance, edustat; 
proc phreg data=der.survival plots(overlay)=survival; 
class outcome agedx race_eth dcismulcent menopause; 
model time_yr*event(0)=outcome agedx race_eth dcismulcent menopause; 
run; 
 
*remove multicentric and race; 
proc phreg data=der.survival plots(overlay)=survival; 
class outcome agedx menopause; 
model time_yr*event(0)=outcome agedx menopause; 
run; 
 
****Model with BRRM vs No BRRM; 
proc phreg data=der.survival plots(overlay)=survival; 
class BRRM agedx race_eth edustat year dcishistogrd insurance dcispathtumsize 
dcismulcent menopause HR; 
model time_yr*event(0)=BRRM agedx race_eth edustat year dcishistogrd 
insurance dcispathtumsize dcismulcent menopause HR; 
run; 
 
*remove HR, year, grade, tumor size; 
proc phreg data=der.survival plots(overlay)=survival; 
class BRRM agedx race_eth edustat insurance dcismulcent menopause; 
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*remove insurance and race; 
proc phreg data=der.survival plots(overlay)=survival; 
class BRRM agedx edustat dcismulcent menopause; 




ods graphics on; 
proc lifetest data=der.survival plots=survival (nocensor); 
strata BRRM; 
time time_yr*event(0); 
test agedx race_eth edustat year dcishistogrd insurance dcispathtumsize 
dcismulcent menopause HR; 
label time_yr='Time in Years'; 
run; 
ods graphics off; 
 
 
 
 
 
 
